Prof. Lotte Steuten, PhD, is Deputy Chief Executive of the not-for-profit Office of Health Economics (OHE) and the scientific and business lead for its international research programme. Alongside her position at OHE, Lotte is a Visiting Honorary Professor at City University of London, President-Elect of ISPOR and an associate editor for Value in Health. Before joining OHE, Lotte worked in Seattle (US) as an Associate Professor at the University of Washington and the Fred Hutch Cancer Research Center. She has an MSc and a PhD (with honours) from Maastricht University (NL) and published >120 peer–reviewed papers.
A 60-minute moderated roundtable begins with a short presentation of the Vaccines Europe study, followed by a discussion exploring:
· Why do vaccine assessment and access pathways differ from those for other medicinal products?
· Which differences are necessary to reflect the specific nature and value of vaccination, and which may contribute to avoidable delays?
· What should be done now to ensure implementation of the EU HTA Regulation is fit for purpose for vaccines?
· What can vaccine assessors learn from HTA of other medicinal products - and what should be approached differently?
· How should NITAG and HTA processes interact as vaccines move towards JCA scope in 2030?